IL6R and inflammatory bowel disease: A pilot phase II study using the neutralising anti-IL-6R antibody tocilizumab suggested a clinical response in Crohn’s disease (CD) patients [26], and several inhibitors of the IL-6 pathway are in clinical development, some also for IBD [3, 14, 27].